• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • MRI Images
  • Sample Access
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

Interview with John Harrison

2020-07-27News

Could you tell us a bit about you?

I am an expert psychologist with a special interest in cognition and its measurement. I have recently been appointed Chief Science Officer at Neurotrack and am Principal Consultant at Metis Cognition, a psychology practice established to advise with the selection and successful integration of cognitive testing into therapeutic development programs. I am also an Associate Professor at the Alzheimer Center of the VUmc in Amsterdam and Visiting Professor at King’s College London.

You are a member of the EPAD Clinical and Cognitive Outcomes Scientific Advisory Group (CCO-SAG). Could you please tell us more about this group, its work and outcomes?

Cognition has a key role and I was delighted when Karen Ritchie and Michael Ropacki asked me to join the CCO-SAG. We were very keen to ensure the work was a transparent process and the initial research reviewing the literature was really helpful as a place to start as we put a natural boundary on the possible ways of thinking about this. After the CCO-SAG met, we published a paper which was essentially an overview of our discussions as well as details of the assessments that we finally determined would be the most useful ones. I think the most obvious immediate outcome was that paper, which has since been very widely cited. You can find the paper here. A further publication followed recently and both papers have hopefully been helpful to people working in the field, both inside and outside of EPAD.

Now we are working into the opportunity to review our work and data. Just a couple of months ago, we completed an analysis of the EPAD baseline data and we have picked out a number of useful pieces of information. We now know much more about EPAD cohort cognitive performance and we are now determining which combination of tests will be the most useful for institutions who want to screen for Alzheimer’s disease. I think we had some reasonably good ideas, but the EPAD process has allowed us to evaluate and test those ideas. We are at the point where we are able to share the findings of the studies we have conducted.

What value do you see in public-private collaboration and networking with related initiatives?

I think one of the really rewarding things about this experience is that you have a strong feeling when you are connected to EPAD, that everybody’s opinion is going to be accounted for, and everybody has a lot to contribute. I’ve long believed that public-private collaborations are amongst the best ways to make progress. This has been true of my own activities, as I spend part of my time conducting academic collaborations and the rest of the time I am working from private organisations, typically pharmaceutical companies. My consultancy is very much a blend of a public-private interaction and I have followed this approach very successfully for the last 20 years. I think this is because the academic side is feeding new information, new findings, new ways of thinking about these issues and the private side, particularly the pharmaceutical and biotech companies, are very good at getting the job done, the combination is very potent.

What are the most prominent challenges you see in Alzheimer’s disease research?

We still have a good number of compounds in the pipeline and we have already seen some value in terms of either preventing progression or giving people some symptomatic relief. The main challenge I see is the need to detect early as possible signs that people are at risk for developing the disease. I think the general public still think that it is a disease of the elderly and our experience is that it is absolutely not always the case. We are seeing much younger people receiving confirmed diagnosis. The big challenge for me is trying to find a methodology that ensures we pick up cases as early as we possibly can, and then make interventions that will slow and perhaps even stop progression.

Share this post
FacebookTwitterLinkedInGoogle+
Related posts
Edinburgh Dementia Prevention Summer School 2022
2022-06-30
EPAD at AAIC22!
2022-06-30
ADDI NeuroToolKit Data Hackathon
2022-05-17
The Neuronet Coordination and Support Action releases updated Decision Tool for engagement with Regulatory and Health Technology Assessment bodies
2022-05-09
First national follow-on study to EPAD LCS launches
2022-04-07
The EPAD genomic data is now available on the Alzheimer’s Disease Workbench
2022-03-10
Latest News
  • Edinburgh Dementia Prevention Summer School 2022
    2022-06-30
  • EPAD at AAIC22!
    2022-06-30
  • ADDI NeuroToolKit Data Hackathon
    2022-05-17
  • The Neuronet Coordination and Support Action releases updated Decision Tool for engagement with Regulatory and Health Technology Assessment bodies
    2022-05-09
  • First national follow-on study to EPAD LCS launches
    2022-04-07
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

The @CenDemPrevent Summer School, a 4-day interactive course on #brainhealth, is designed for clinicians, researchers and students. Space is limited, sign up quickly! 🗓️26-29 September 📍Edinburgh For more info, including programme⤵️ ep-ad.org/edinburgh-deme… pic.twitter.com/FSypbvWK4L

reply retweet favorite
12:38 pm · 2022-06-30
Twitter
EPAD
EPAD
@IMI_EPAD

There’s still time to join the @AlzData #NeuroToolKit #Data Hackathon! Registration closes on 24 June! Participants will work with @IMI_EPAD datasets and utilise the tools on the #ADWorkbench. Interested in participating? ➡️alzheimersdata.org/hackathon twitter.com/IMI_EPAD/statu…

reply retweet favorite
7:21 am · 2022-06-22
Twitter
EPAD
EPAD
@IMI_EPAD

Today, colleagues from @AlzData visited @CenDemPrevent to meet with those involved in various programmes including @IMI_EPAD @AD_PREVENT. Many relevant discussions and great catch-up! #BrainHealth #datasharing #collaboration @craig_ritchie68 @samdansobe @GregorySarah @CindyBirck pic.twitter.com/Mr3trKeuoz

reply retweet favorite
2:43 pm · 2022-06-15
Twitter
EPAD
EPAD
@IMI_EPAD

Have a look on the new @AlzheimerEurope #DementiaInEurope magazine featuring an article on @IMI_EPAD and its collaboration with @AlzData to make our data findable, accessible and reusable. @craig_ritchie68 ⤵️ alzheimer-europe.org/resource… twitter.com/AlzheimerEurop… pic.twitter.com/vLuW3HMLUh

reply retweet favorite
1:09 pm · 2022-06-14
Twitter
EPAD
EPAD
@IMI_EPAD

Registration will close tomorrow! Register now for the free #Brainhealth2022 conference, taking place next week in Edinburgh ⤵️ brainhealth.scot/brainhealth2… twitter.com/IMI_EPAD/statu…

reply retweet favorite
3:05 pm · 2022-06-09
Copyright © 2015-2021 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT